In recent years, the rise of alternative treatments for cancer has gained momentum, with Fenbendazole 444 making headlines as a potential option. Originally developed as a dewormer for Fenbendazole has caught the attention of researchers and cancer patients alike, raising questions about its off-label use in oncology.
